Clinical Pharmacology & Therapeutics

1. In this Issue

   Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 9-10, July 2025.

2. Highlighted Articles

   Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 14-15, July 2025.

3. ASCPT News

   Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 16-22, July 2025.

4. Drug Interactions Brewing

   Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 11-13, July 2025.

5. Issue Information

   Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 1-6, July 2025.

6. Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective

   Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 62-73, July 2025.

7. ICH M12 Drug Interaction Studies: Summary of the Efforts to Achieve Global Convergence

   Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 33-44, July 2025.

8. Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes

   Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 74-79, July 2025.

9. Green Tea Catechins as Perpetrators of Drug Pharmacokinetic Interactions

   Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 45-61, July 2025.

10. Real‐World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020–2022

    Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 85-89, July 2025.

11. Participants in the FDA's Biomarker Qualification Program

    Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 80-84, July 2025.

12. The Drug Titration Paradox Updated and Reinterpreted: With Perfect Titration, Dose and Effect Will Be Uncorrelated

    Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 90-94, July 2025.

13. Chat GPT and the Challenges to Detect Potential Drug–Drug Interactions Related to QT Prolongation

    Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 23-23, July 2025.

14. Reply to “Chat GPT and the Challenges to Detect Potential Drug–Drug Interactions Related to QT Prolongation”

    Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 24-24, July 2025.

15. Translational Modeling as a Tool to Evaluate the Effectiveness of Nalmefene in a Community Setting: A Critical Perspective

    Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 25-26, July 2025.

16. Reply to “Translational Modeling as a Tool to Evaluate the Effectiveness of Nalmefene in a Community Setting: A Critical Perspective”

    Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 27-28, July 2025.

17. Frequency and Nature of Generic “Design Around” of Brand‐Name Patents in the United States

    Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 190-194, July 2025.

18. Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis

    Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 95-105, July 2025.

19. Regulatory Approval of CAR‐T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan

    Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 118-127, July 2025.

20. Impact of Cancer Cachexia Progression on OATP1B1 Transport Activity: Quantitative Analysis Using Coproporphyrin‐I as an Endogenous Biomarker

    Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 128-137, July 2025.